Brian has been with PIPV Capital since 2004. He leads the review and scientific due diligence efforts for the firm for both developmental stage and marketed assets.
Brian works with PIPV’s portfolio companies in multiple areas including business development and financial modeling. He is currently Vice President of Corporate Development for Glycan Biosciences, a biotech company with a carbohydrate based chemistry platform used to development products for inflammatory diseases. In Glycan, Brian successfully managed a transaction to out license a non-core asset of the company.
Brian also works in another PIPV portfolio company, Iroko Pharmaceuticals in Corporate Development and Alliance Management. He has been involved in many aspects of the business including managing relationships with Iroko’s international partners and has led projects related to API manufacturing, distribution and commercialization. He also works with the finance group in forecasting and modeling as well as managing internal and external diligence processes.
Previously, Brian provided scientific and business development consulting services to ZaBeCor Pharmaceuticals, a development stage biotechnology company. During his time at ZaBeCor, the lead asset, an siRNA for asthma, progressed from a preclinical stage asset to completing a Phase 2 clinical trial.
Brian holds a B.S. from the University of Richmond and a Ph.D. in Immunology from the University of Pennsylvania School of Medicine.